EP3403666A1 - Modifikation und zusammensetzungen menschlicher sekretoglobinproteine - Google Patents

Modifikation und zusammensetzungen menschlicher sekretoglobinproteine Download PDF

Info

Publication number
EP3403666A1
EP3403666A1 EP18167516.6A EP18167516A EP3403666A1 EP 3403666 A1 EP3403666 A1 EP 3403666A1 EP 18167516 A EP18167516 A EP 18167516A EP 3403666 A1 EP3403666 A1 EP 3403666A1
Authority
EP
European Patent Office
Prior art keywords
protein
rhcc10
modified
unmodified
secretoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18167516.6A
Other languages
English (en)
French (fr)
Inventor
Aprile L. Pilon
Humcha K. Hariprakasha
Richard S. Clayton
Melissa E. Winn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therabron Therapeutics Inc
Original Assignee
Therabron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabron Therapeutics Inc filed Critical Therabron Therapeutics Inc
Publication of EP3403666A1 publication Critical patent/EP3403666A1/de
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Definitions

  • the field of the invention pertains to chemically or enzymatically modified preparations of synthetic secretoglobins that have altered or enhanced properties compared to the unmodified versions. More specifically, modification of recombinant human secretoglobin proteins using reactive oxygen species (ROS), reactive nitrogen species (RNS), enzyme catalyzed modification such as myeloperoxidase plus hydrogen peroxide, or transglutaminase catalyzed modification.
  • ROS reactive oxygen species
  • RNS reactive nitrogen species
  • the invention further pertains to characterization of new isoforms of modified secretoglobins, optimized processes for modifying secretoglobins, and isolation of secretoglobin isoforms.
  • isoform herein refers to a secretoglobin or CC10 monomer, dimer, or other multimer complex that contains intact monomers of at least 60 amino acids in length that contain one or more chemically modified amino acids.
  • the invention further pertains to alteration of the biological activity, change in the structural conformation, or biochemical properties of a secretoglobin by chemical or enzymatic modification of one or more of its amino acids.
  • the invention further pertains to enhancing the anti-viral activity of rhCC10 through chemical modification with ROS, RNS, and enzyme-catalyzed amino acid modification.
  • the invention further pertains to enhancing the inhibition of neutrophil migration by rhCC 10 through chemical modification with ROS, RNS, and enzyme-catalyzed amino acid modification.
  • Secretoglobins are a family of structurally related proteins comprised of four helical bundle monomers that form disulfide dimers, tetramers and higher multimers.
  • human secretoglobins Figure 1
  • Clara Cell 10kDa protein CC10
  • Clara Cell 16 kDa protein CC16
  • Clara Cell secretory protein CCSP
  • blastokinin urine protein-1
  • secretoglobin 1A1 SCGB1A1
  • Secretoglobins and CC10 are believed to exist in all vertebrate animals. Based on what is known of CC10, secretoglobins are thought to play a role in regulating immune responses, although the physiologic roles and specific mechanisms of these proteins, including CC10 remain unknown.
  • CC10 The primary source of CC10 in mammals is the pulmonary and tracheal epithelia, especially the non-ciliated bronchiolar airway epithelial cells (primarily Clara cells), and it is the most abundant locally-produced protein in the extracellular fluids of the adult lung. It is also secreted in the nasal epithelia. CC10 is also present in serum and urine, which is largely derived from pulmonary sources.
  • CC10 is also produced by reproductive tissues (uterus, seminal vesicles), exocrine glands (prostate, mammary gland, pancreas), endocrine glands (thyroid, pituitary, adrenal, and ovary) and by the thymus and spleen (Mukherjee, 1999; Mukherjee, 2007).
  • the major recoverable form of human CC10 in vivo is a homodimer, comprised of two identical 70 amino acid monomers, with an isoelectric point of 4.7-4.8. Its molecular weight is 15.8 kDa, although it migrates on SDS-PAGE at an apparent molecular weight of 10-12 kDa.
  • the monomers are arranged in an antiparallel configuration, with the N-terminus of one adjacent to the C-terminus of the other and are connected by two disulfide bonds between Cys3 of one monomer and Cys69 of the other monomer (Mukherjee, 1999).
  • secretoglobins undergo cleavage of N-terminal signal peptides, which is an integral part of the secretion process in mammalian cells. But they are not known to be glycosylated or lipidated. However, secretoglobins are subjected to the same processes that affect all other proteins in the extracellular milieu during an inflammatory response.
  • Native CC10 is chemically modified in vivo and new forms of native CC10 have been identified in patient samples that are not present in samples from normal humans (Lindhal, 1999; Ramsay, 2001; Ariaz-Martinez, 2012).
  • Synthetic CC10 protein may be made by recombinant or chemical synthetic methods (Barnes, 1996; Mantile, 1993; Nicolas, 2005).
  • CC10 is the most well-known member of a family of structurally related proteins collectively called secretoglobins (Klug, 2000).
  • the amino acid sequences for the mature secreted sequences of eight human secretoglobins are shown in Figure 1 .
  • the N-termini are predictions based on consensus signal peptide cleavage sites and have not been confirmed by N-terminal sequencing of the native proteins. All secretoglobins share a conserved four helical bundle secondary structure and, therefore, generally believed to mediate similar physiological functions.
  • ROS Reactive oxygen species
  • RNS reactive nitrogen species
  • Common ROS and RNS chemical reagents that mediate protein oxidation in vivo include hydrogen peroxide (N 2 O 2 ), Fe 2+ , Cu 1+ , glutathione, HOCl, HOBr, 1 O 2 , and ONOO - .
  • ROS and RNS may be synthesized or released in vivo as a result of enzyme activity, such as myeloperoxidase, xanthine oxidase, and P-450 enzymes, and oxidative burst activity of activated phagocytic cells.
  • Lipid peroxides such as 4-hydroxy-2-trans-nonenal (HNE), (MDA), and acrolein are the products of reactions of ROS and RNS with lipids that are, in turn, highly reactive and can form adducts with proteins.
  • HNE 4-hydroxy-2-trans-nonenal
  • MDA 2-hydroxy-2-trans-nonenal
  • acrolein are the products of reactions of ROS and RNS with lipids that are, in turn, highly reactive and can form adducts with proteins.
  • ROS and RNS are indiscriminate chemically reactive agents that destroy essential biological components including nucleic acids, lipids (including membrane and surfactant phospholipids), and proteins, in both the pathogen and host, often causing significant tissue damage that may be more life-threatening than the original infection or other cause of the inflammatory response.
  • ARDS acute respiratory distress syndrome
  • Pneumonia an acute lung infection
  • ROS and RNS typically has a 40-60% mortality rate due to pulmonary tissue damage that compromises lung function, even after the pathogen causing the infection is brought under control using anti-microbial agents.
  • oxidative protein modifications There are several types of oxidative protein modifications, the most common of which is sulfur oxidation in which disulfide bonds between cysteines (Cys), S-thiolation, and methionine (Met) sulfoxide are formed. Protein carbonyl groups are also common oxidative modifications in which amino acid side chains are converted to aldehydes and ketones, especially lysine (Lys) arginine (Arg), and proline (Pro). Aliphatic amino acids may be converted to their hydro(pero)xy derivatives. Chloramines and deaminations may occur.
  • Certain amino acids may be converted into other amino acids, such as histidine (His) to asparagine (Asn), while others may form lipid peroxidation adducts, amino acid oxidation adducts (eg. p -hydroxyphenylacetaldehyde), and glycoxidation adducts (eg. carboxymethyllysine).
  • His histidine
  • Amin amino acid oxidation adducts
  • glycoxidation adducts eg. carboxymethyllysine.
  • cross-links, aggregation, and peptide bond cleavage may occur as a result of exposure to ROS and RNS.
  • cysteine (Cys) and methionine (Met) are the most susceptible to oxidation and, unlike oxidation of other amino acids, the oxidation of Met and Cys are reversible (methionine sulfoxide reductase and glutathione and thioredoxin redox systems) (Stadtman, 2002).
  • TGs transglutaminase enzymes
  • TGs are ubiquitous in nature, found in all forms of life from microbes to mammals. TGs are essential to several inter- and intracellular processes in mammals, including extracellular matrix synthesis, neutrophil and monocyte adhesion and motility, receptor endocytosis, pinocytosis, antigen uptake and processing, blood clotting, G-protein signaling, and apoptosis (reviewed in Lorand, 2003).
  • TGs are multi-functional enzymes that mediate at least one main enzymatic activity; the classical transglutaminase activity in which a glutamine residue in one protein serves as an acyl donor and a lysine residue in a second protein serves as the acyl acceptor. TGs also mediate deamidation and esterification of proteins, as well as the creation and rearrangement of disulfide bonds between cysteine residues. None of these activities has an energy requirement and the only cofactor necessary is calcium.
  • Transglutaminases play a significant role in inflammation and immunity, particularly TG2 or tissue transglutaminase. It is present mostly in the cytoplasm but a portion of the enzyme is associated with the membrane on the cell surface and is known to be a coreceptor for fibronectin. TGs have also been shown to cross-link proteins to specific lipid moieties in membranes, allowing a lipid barrier to be created on a structural protein scaffold in skin (Lesort, 2000; Nemes, 1999). More recently, the emerging role of TGs in viral infection has been recognized (reviewed in Jeon, 2006). Intracellular TG2 is normally present in an inactive state and is activated by oxidative stress and calcium mobilization resulting from viral infection.
  • TG2 Activated intracellular TG2 mediates its anti-viral activities via direct modification/inactivation of viral proteins, as well as modification of cellular proteins required for viral entry, replication, assembly, or transport.
  • CC10 has been previously shown to be a substrate for TG2 (Mukherjee, 1988).
  • CC10 is cross-linked to other CC10 molecules by TG2, to form covalently attached multimers and aggregates observed on SDS-PAGE gels and Western blots.
  • no other TG-mediated reaction products of CC10 or other secretoglobin have been characterized.
  • a primary object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic secretoglobin (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic CC10 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB3A2 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB3A1 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB2A1 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB2A2 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB1D1 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB1D2 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of an oxidatively or enzymatically modified synthetic SCGB1D4 (whether made by recombinant or chemical methods).
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more methionine sulfoxides.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more cysteine glutathiolates.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more HNE-cysteines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more nitrotyrosines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more di-tyrosines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more carbonyl groups.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing a combination of two or more modified amino acids selected from the groups consisting of methionine sulfoxide, nitrotyrosine, or di-tyrosine.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more chlorotyrosines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more hydroxyprolines, pyrrolidones, or glutamic semialdehydes.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more 2-amino-3-ketobutyric acids.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more chloramines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more -aminoadipic semialdehyde, chloramines, MDA-Lys, HNE-Lys, acrolein-Lys, carboxymethyllysine, or pHA-Lys.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more hydroxytryptophan, nitro-tryptophan, or kynurenines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more valine or leucine peroxides.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more oxalic or pyruvic acids.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more hydroxyphenylalanines.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more glutamic semialdehydes.
  • a further object of the invention is a composition of matter comprised of a modified synthetic secretoglobin containing one or more 2-oxohistidine or HNE-His.
  • a further object of the invention is a composition of matter containing a combination of an unmodified synthetic secretoglobin and an oxidatively or enzymatically modified synthetic secretoglobin, wherein the unmodified and modified preparations are the same secretoglobin.
  • a further object of the invention is a composition of matter containing a combination of an unmodified synthetic secretoglobin and an oxidatively or enzymatically modified synthetic secretoglobin, wherein the unmodified and modified preparations are not the same secretoglobin.
  • a further object of the invention is a composition of matter containing a combination two or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are the same secretoglobin.
  • a further object of the invention is a composition of matter containing a combination two or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are not the same secretoglobin.
  • a further object of the invention is a composition of matter containing a combination one or more unmodified synthetic secretoglobin and one or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are the same secretoglobin.
  • a further object of the invention is a composition of matter containing a combination one or more unmodified synthetic secretoglobin and one or more oxidatively or enzymatically modified synthetic secretoglobins, wherein the unmodified and modified preparations are not the same secretoglobin.
  • a secondary object of the invention is a pharmaceutical composition containing a modified synthetic secretoglobin that can be used as a therapeutic agent.
  • a further object of the invention is a pharmaceutical composition containing a combination of two or more modified synthetic secretoglobins that can be used as a therapeutic agent.
  • a further object of the invention is a pharmaceutical composition containing a combination of unmodified and modified synthetic secretoglobins that can be used as a therapeutic agent. It is a further object of the invention to administer a modified synthetic secretoglobin to a patient with an inflammatory condition or a viral infection.
  • a further object of the invention is a process in which chemical oxidation is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which a reactive oxygen species (ROS) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • ROS reactive oxygen species
  • a further object of the invention is a process in which a reactive nitrogen species (RNS) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • RNS reactive nitrogen species
  • a further object of the invention is a process in which sodium hypochlorite (NaOCl) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which hypochlorite (HOCl) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which metachloroperbenzoic acid (mCPBA) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • mCPBA metachloroperbenzoic acid
  • a further object of the invention is a process in which hydrogen peroxide (H 2 O 2 ) is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which an enzyme is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which myeloperoxidase is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which transglutaminase is used to convert an unmodified synthetic secretoglobin into a modified synthetic secretoglobin.
  • a further object of the invention is a process in which transglutaminase is used to attach a label, chemical, lipid, or peptide moiety to an unmodified synthetic secretoglobin.
  • the invention relates to chemical and/or enzymatic modification of synthetic secretoglobins in order to alter or enhance biological or biochemical properties compared to the unmodified versions.
  • Chemical reagents such as reactive oxygen species (ROS), and reactive nitrogen species (RNS), or enzymes such as myeloperoxidase or transglutaminase, are used to achieve the amino acid modifications.
  • ROS reactive oxygen species
  • RNS reactive nitrogen species
  • the addition of lipid and other moieties to secretoglobins is also mediated by TGs.
  • the invention further relates to optimization of chemical or enzyme-mediated processes to achieve amino acid modifications, as well as biochemical and physical characterization of mixtures of modified secretoglobins, and isolation and characterization of individual secretoglobin isoforms.
  • isoform refers to a secretoglobin monomer, dimer, or other multimer complex that contains monomer units of at least 60 amino acids in length, but preferably full length monomers that are at least 75% identical to the amino acid sequences shown in Figure 1 , that contain one or more chemically modified amino acids.
  • Biological properties including, but not limited to, inhibition of viral replication and inhibition of neutrophil chemotaxis may be altered or enhanced in the chemically modified secretoglobin mixtures and isoforms.
  • CC10 is modified during acute inflammatory responses in vivo, such as in respiratory distress, giving rise to new isoforms thus far identified by cross-reactivity with anti-CC10 antibodies and isoelectric points different from unmodified CC10 (pI ⁇ 4.8), which is the predominant form in biological fluid samples. It has also been reported that CC10 is a substrate for tissue transglutaminase in vitro. Other than the role for Cys residues in stabilizing multimers and controlling access to the central hydrophobic cavity, there is no known physiological role for oxidation of any amino acid in any secretoglobin.
  • oxidative and/or enzymatic modification of other secretoglobin amino acids such as tyrosine, lysine, glutamine, valine, leucine, phenylalanine, glutamate, arginine, threonine, proline, histidine, and tryptophan do not represent protein damage, but rather modulate biochemical and biological properties that enable different or enhanced activities.
  • cysteines in secretoglobins are potentially susceptible to oxidation and the formation of intra- or intermolecular disulfide bonds, particularly the respiratory secretoglobins, CC10, SCGB3A1, and SCGB3A2.
  • the disulfide bonds between N- and C-terminal Cys in CC10 certainly stabilize the homodimer in conditions that would otherwise break apart the dimer into monomers, such as in non-reducing SDS-PAGE conditions.
  • the internal Cys of SCGB3A2 (Cys60 of the sequence shown in Figure 1 ) stabilizes the homodimer in vitro. No particular functionality is ascribed to the dimer versus the monomer or other multimers of CC10 or SCGB3A2.
  • CC10 and SCGB3A2 both form homodimers spontaneously in vitro without any requirement for an oxidizing agent, it has not been possible to evaluate differences in biochemical properties or biological activities of forms other than the dimer. These homodimers are very stable in vitro, although there is an equilibium between monomer and dimer in any given aqueous environment and it is possible to change buffer conditions to favor a higher percentage of monomer and/or tetramer with respect to dimer.
  • the dimer is the initial form administered to humans and animals, numerous reducible and non-reducible forms can be recovered from biological fluids (Antico, 2006).
  • the in vivo glutathione redox system in the lungs likely mediates reversible oxidation of disulfide bonds in the respiratory secretoglobins and other secretoglobins that may be found in the lungs.
  • a physiological role for CC10 has been proposed to be the scavenging of toxic or otherwise harmful hydrophobic moieties that may be taken up and bound into the central hydrophobic cavity and thereby removed from the local tissue environment (Peter, 1992; Hard, 1995; Umland, 1992; 1994).
  • the disulfide bonds between the Cys residues (Cys3 and Cys69) of the monomer components in each CC10 dimer are believed to act like a gate that opens and closes by reversible oxidation of the Cys residues to form and break the disulfide bonds to allow entry of a hydrophobic moiety into the central hydrophobic cavity, then trap it there.
  • All secretoglobins contain significant proportions of amino acids that are susceptible to oxidative and enzymatic amino acid modification.
  • Each 70 amino acid monomer of CC10 contains a total of 42 amino acids (out of 70; >50%), listed in Table 1, that can be oxidized by physiologic processes involving ROS and RNS, leaving open the possibility of a large number of ROS and RNS reaction products, aka isoforms.
  • TG can also be used to attach lipid or other moieties to secretoglobins via their glutamine, lysine, and cysteine residues, and not just cross-link secretoglobins to other proteins.
  • rhCC10 in which oxidative and enzymatic modifications give rise to multiple isoforms that can be isolated and characterized.
  • Preparations containing oxidatively modified rhCC 10 also mediated enhanced of inhibition of viral replication and neutrophil chemotaxis, representing significant improvements on the existing unmodified CC10 drug preparation.
  • rhCC 10 preparations modified in vitro as standards to assess CC10 isoforms contained within, or isolated from, biological samples enables the evaluation of native CC10 isoforms as biomarkers of pulmonary status in chronic diseases and acute conditions.
  • a secretoglobin may have no effect on a particular cell type, but has a different effect after modification because the modification enabled or disabled binding to a cell surface receptor, cell signaling molecule, lipid, ligand, structural protein, or other intra- or extracellular component.
  • reaction was initiated at ⁇ 4°C (on ice) by adding NaOCl (9.2 L; 0.05% solution in water, 62.1 nmol, 5 equivalents) to a solution of the protein (0.2 mg, 12.42 nmol) in 10 mM phosphate buffer, pH 7.4 or plain water, mixing briefly and incubating on ice for 15 minutes in the dark (total volume of 0.2 mL).
  • the reaction was quenched by adding L-methionine (9.3 L; 10mM in water, 93.15 nmol), then incubated for 20 min and warmed to room temperature.
  • Oxidation of rhCC10 was monitored using HPLC, in which new modified isoforms appeared as new HPLC peaks, eluting earlier than unmodified rhCC10, as shown in Figure 2 . Reactions were concentrated by Speedvac and then resuspended in water.
  • the extent of the chemical reaction and modification of rhCC10 can be estimated by the detection of reactive carbonyl groups.
  • the presence of carbonyl groups in ROS-reacted rhCC10 samples can be detected by labeling the carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH), which adds a dinitrophenylhydrazone group (DNP), then analyzing the reaction products by Western blot using anti-DNP antibody as shown in Figure 6 .
  • DNPH 2,4-dinitrophenylhydrazine
  • DNP dinitrophenylhydrazone group
  • Oxidation of rhCC10 was monitored using HPLC. Reactions were concentrated in a Speedvac and then resuspended in water. Approximately 25 g of each sample was injected onto the HPLC, as with the NaOCl reactions. New modified isoforms appeared as new HPLC peaks, eluting earlier than unmodified rhCC10, as shown in Figure 7 . Isoelectric focusing of the mCPBA reactions, shown in Figure 8 , revealed that multiple new isoforms were generated, including a cluster of new isoforms in the pI 4.5-5.2 range (4.6, 4.7, 4.9, 5.1, 5.2), two isoforms above 5.3 ( ⁇ 5.5, ⁇ 5.8) and one isoform below 4.5 ( ⁇ 4.3).
  • the isoforms below the main immunoreactive band at 4.8 also showed less signal than would be expected based on the intensity of staining in the IEF gel.
  • Further analysis of reaction conditions showed that the presence of CaCl 2 could prevent modification of rhCC 10 by mCPBA ( Figure 10 , lane 2), that 100 eq mCPBA completely eliminates all of the original unmodified protein leaving only more acidic isoforms (pIs 4.0, 4.3, 4.5; lane 4), and that rhCC10 is destroyed if the reaction is run too long (lane 3).
  • CC10 isoforms generated in the mCPBA reaction a protein sample of each of 8 separate major HPLC peaks (numbered 1-8) was collected, concentrated using a Speedvac, and verified by repeat HPLC to represent a single peak; for example peak 3, as shown in Figure 11 . The samples were then analyzed by electrospray mass spectrometry (ESI-MS) to obtain molecular weights for each isoform. Table 2 shows the results of the MS analysis of isoforms contained in individual HPLC peaks. All CC10 isoforms had a greater molecular weight (MW) than the unmodified form, which has a MW of 16,110 daltons (Da). The addition of an oxygen adds 16 Da.
  • MW molecular weight
  • Da 16,110 daltons
  • Example 3 Chemical modification of rhCC10 by ROS: myeloperoxidase enzyme (MPO) and hydrogen peroxide (H 2 O 2 )
  • CC10 isoforms generated in the MPO-H 2 O 2 reactions a protein sample of each of 8 major separable HPLC peaks (numbered 9-17) was collected, concentrated using a Speedvac, and verified by repeat HPLC to represent a single peak; for example peak 10, as shown in Figure 16 . The samples were then analyzed by electrospray mass spectrometry (ESI-MS) to obtain molecular weights for each isoform. Table 3 shows the results of the MS analysis. All CC10 isoforms had a greater molecular weight (MW) than the unmodified form, which has a MW of 16,110 daltons (Da).
  • MW molecular weight
  • Da 16,110 daltons
  • CC10 monomer contains a single tyrosine, which these results show is susceptible to nitration in the presence of RNS.
  • intermolecular bonds may form di-tyrosine complexes in different monomers.
  • the isoforms generated by the peroxynitrite reactions were largely intact CC10 with larger covalently linked complexes as shown by Western blot of SDS-PAGE in Figure 19 .
  • CC10 peroxynitrite reactions were run under non-reducing conditions in a 1-10% SDS-PAGE tricine gel, which was blotted to PVDF membrane, blocked with 4% non-fat milk, and probed with rabbit polyclonal anti-nitrotyrosine antibody.
  • the blot shows immunoreactive CC10 dimers, tetramers, and "smears" of higher molecular weight complexes, proving that the tyrosine residue in the CC10 monomer is susceptible to modification. Nitration of tyrosine does not disrupt dimer or tetramer stability. This pattern further indicates that tyrosine nitration favors the formation of large complexes, likely linked together by both di-tyrosines and disulfide bonds, but does not generate the distinct sets of thermodynamically favored multimers achieved by simple disulfide bond rearrangements in the absence of di-tyrosine formation.
  • CC10 was shown to be an in vitro substrate of tissue transglutaminase (aka TG2) (Manjunath, 1984), and is cross-linked to itself and other proteins via glutamine and lysine residues. Determination of availability of glutamine in uteroglobin as an acyl donor/amine acceptor was performed using biotin linked to two different monoamine groups. Purified guinea pig liver transglutaminase and monoamine-biotin reagents; 5-(Biotinamido)pentylamine and (+)-Biotinyl-3,6-dioxaoctanediamine; were purchased from a commercial vendor.
  • the reactions were performed in 25 mM Tris/150 mM NaCl pH 8.0 with 1.5 mM DTT. Where applicable, CaCl 2 was used at a final concentration of 4.5 mM.
  • Calcium is a TG cofactor required for the crosslinking of glutamine and lysine residues. In the absence of calcium and reducing agent, TG2 mediates a rearrangement of disulfide bonds in CC10, resulting in formation of a "ladder" of multimers that can be reduced with a reducing agent (not shown).
  • the protein and amine of interest were combined in buffer with or without calcium to an assay volume of 0.1 mL. Samples were pre-incubated at 37°C for 30 minutes prior to the addition of the transglutaminase.
  • EDTA at a final concentration of 50 mM was added to the samples without calcium and acted as negative controls. After the pre-incubation 5 U of transglutaminase was added to each tube and the reaction was allowed to proceed at 37°C for 60 minutes. After 60 minutes EDTA (50 mM) was added to the tubes containing calcium to stop the reaction. One hundred L of SDS sample buffer plus reducing agent (1 mM DTT) was added to each reaction, which were then heated at 95°C for 10 minutes prior to separation on a SDS-PAGE gel. The gel was blotted to a PVDF membrane. Blocking was done for 1 hour at room temperature using 5% BSA (filtered through a 2 micron membrane).
  • the non-reducible high molecular weight bands indicate that CC10 contains at least two reactive glutamine - lysine pairs, since the high molecular weight bands represent cross-linked CC10 with at least one glutamine-amine biotin amine per complex (such that a single monomer is both labeled with the biotin tag and cross-linked to at least one other monomer).
  • moieties such as labels, chemicals, lipids, and peptides containing primary amine groups may be added to rhCC10 using TG2 in the presence of calcium and a reducing agent while other moieties containing sulfhydryl groups may be added to rhCC10 using TG in the absence of a reducing agent.
  • Example 6 Enhanced inhibition of influenza replication in vitro by modified rhCC10 compared to unmodified rhCC 10
  • rhCC10 In order to determine the effect of modification on the activity of rhCC10, a single pool of modified rhCC10 was made by combining equal aliquots of rhCC10 reactions with NaOCl, mCPBA, MPO+H 2 O 2 , and peroxynitrite. All HPLC peaks from each reaction were represented in the pool. Modified and unmodified rhCC 10 preparations were diluted in eight half-log dilutions in MEM solution at the highest concentrations possible with the sample available. Each dilution was added to 5 wells of a 96-well plate with 80-100% confluent MDCK cells.
  • Example 7 Enhanced inhibition of neutrophil chemotaxis in vitro by modified rhCC10 compared to unmodified rhCC 10
  • Human PLB-985 cells are an immature myeloid leukemia cell line that can be differentiated in vitro essentially into mature human neutrophils (Pedruzzi, 2002). The differentiated PLB-985 cells can then be used as surrogates for actual human neutrophils isolated from peripheral blood in neutrophil function assays such as chemotaxis in response to a variety of stimuli, including fMLP.
  • fMLP is a formylated peptide (Met, Leu, Pro) that is produced only by bacteria and is a signal of bacterial overgrowth to the body that elicits a potent anti-inflammatory response, including migration of neutrophils along a concentration gradient towards the source of the fMLP. Both unmodified and modified rhCC10 were evaluated as inhibitors of differentiated PLB-985 (dPLB-985) in this model.
  • PLB-985 cells were cultured in medium supplemented with 300 ⁇ M dibutyril cyclic AMP for 3 days before each experiment. Differentiated PLB-985 cells were resuspended in RPMI-1640 (without phenol red) containing 10% FBS (RPMI/FBS) at 10 7 cells/ml.
  • the cells were pre-incubated with 5 ⁇ g/ml calcein-acetoxymethyl ester at 37°C for 30 min in the dark with constant agitation. The cells were then washed and resuspended in RPMI/FBS at 2 ⁇ 10 6 cells/ml. The dPLB-985 cells were incubated with 100 mcg/ml rhCC10 preparations at 37°C for 60 min or PBS (50%). Cell migration was monitored using a 96-well ChemoTX disposable chemotaxis system (Neuro Probe). The wells of the lower chamber of the plate were filled with 32 ⁇ l of fMLP at 10 -8 M.
  • the polycarbonate filters (3 ⁇ M) were positioned on the plate, and dPLB-985 cells (30 ⁇ l; 60,000 cells/well) were placed on the filter and allowed to migrate for 120 min at 37°C in the presence of 5% CO 2 in the dark. The cells that had not migrated were removed by gently wiping the filters with a tissue.
  • Secretoglobin A type of protein that includes human and non-human proteins in the CC10 family having the conserved four helical bundle motif and ranging in size from about 50-100 amino acids in length. Human secretoglobins are shown in Figure 1 .
  • Synthetic secretoglobin A secretoglobin that is made by chemical or recombinant process and not isolated from a natural source.
  • Unmodified secretoglobin protein A secretoglobin monomer, dimer, or other multimer that does not contain chemically or enzymatically modified amino acid residues, other than spontaneously occurring disulfide bonds between cysteine residues in homodimers and heterodimers.
  • Unmodified CC10 protein A CC10 monomer, dimer, or other multimer that does not contain chemically or enzymatically modified amino acid residues, other than disulfide bonds between cysteine residues.
  • Modified secretoglobin A secretoglobin monomer, dimer, or other multimer, that contains one or more chemically or enzymatically modified amino acid residues.
  • Modified synthetic secretoglobin A synthetic secretoglobin monomer, dimer, or other multimer, that contains one or more chemically or enzymatically modified amino acid residues.
  • Modified CC10 A CC10 monomer, dimer, or other multimer, that contains one or more chemically or enzymatically modified amino acid residues.
  • Modified recombinant human CC10 A CC10 monomer that is made by recombinant DNA methods and contains one or more chemically or enzymatically modified amino acid residues.
  • Modified synthetic CC10 A CC10 monomer made by either recombinant DNA or chemical peptide synthetic methods that contains one or more chemically or enzymatically modified amino acid residues.
  • Modified amino acid residues An amino acid in a protein whose side chain has been modified from the form originally present upon completion of translation of the protein.
  • the chemical structure of the 20 natural unmodified amino acids found in proteins can be found in any biochemistry textbook.
  • Carbonyl group An aldehyde or ketone group on an amino acid side chain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
EP18167516.6A 2013-03-15 2014-03-17 Modifikation und zusammensetzungen menschlicher sekretoglobinproteine Pending EP3403666A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,773 US9394349B2 (en) 2013-03-15 2013-03-15 Modification and compositions of human secretoglobin proteins
PCT/US2014/030117 WO2014145368A2 (en) 2013-03-15 2014-03-17 Modification and novel compositions of human secretoglobin proteins
EP14765106.1A EP2968449A4 (de) 2013-03-15 2014-03-17 Modifikation und neuartige zusammensetzungen menschlicher sekretoglobinproteine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP14765106.1A Division EP2968449A4 (de) 2013-03-15 2014-03-17 Modifikation und neuartige zusammensetzungen menschlicher sekretoglobinproteine

Publications (1)

Publication Number Publication Date
EP3403666A1 true EP3403666A1 (de) 2018-11-21

Family

ID=51530119

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18167516.6A Pending EP3403666A1 (de) 2013-03-15 2014-03-17 Modifikation und zusammensetzungen menschlicher sekretoglobinproteine
EP14765106.1A Withdrawn EP2968449A4 (de) 2013-03-15 2014-03-17 Modifikation und neuartige zusammensetzungen menschlicher sekretoglobinproteine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14765106.1A Withdrawn EP2968449A4 (de) 2013-03-15 2014-03-17 Modifikation und neuartige zusammensetzungen menschlicher sekretoglobinproteine

Country Status (13)

Country Link
US (4) US9394349B2 (de)
EP (2) EP3403666A1 (de)
JP (2) JP6670987B2 (de)
KR (1) KR20160030076A (de)
CN (1) CN105744946A (de)
AU (1) AU2014233127A1 (de)
BR (1) BR112015021266A2 (de)
CA (1) CA2907439A1 (de)
IL (1) IL241417A0 (de)
MX (1) MX2015013092A (de)
RU (1) RU2015144360A (de)
SG (1) SG11201507277YA (de)
WO (1) WO2014145368A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
CN107108708A (zh) * 2014-12-22 2017-08-29 加州大学评议会 用于生成抗原、抗体的组合物和方法以及免疫治疗性组合物和方法
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
AU2019387570A1 (en) * 2018-11-30 2021-07-15 Apc Research Assets Llc Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617965A1 (de) * 1993-03-15 1994-10-05 Marc Jozef Philemon De Ley Clarazell-Protein CC10 enthaltendes pharmazeutisches Präparat und seine Verwendung als Arzneimittel und Diagnostikum
WO2007109118A2 (en) * 2006-03-16 2007-09-27 Cc 10 Sweden Ab RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
WO2011047065A1 (en) * 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047857A1 (en) * 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
WO2000009741A1 (en) 1998-08-13 2000-02-24 The Trustees Of The University Of Pennsylvania Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
US7655413B2 (en) 2003-06-26 2010-02-02 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CN1580261A (zh) * 2003-08-06 2005-02-16 上海富纯中南生物技术有限公司 Cc10蛋白的制备及应用
TW200526251A (en) 2003-11-14 2005-08-16 Alza Corp Minimization of drug oxidation in drug irradiated excipients formulations
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617965A1 (de) * 1993-03-15 1994-10-05 Marc Jozef Philemon De Ley Clarazell-Protein CC10 enthaltendes pharmazeutisches Präparat und seine Verwendung als Arzneimittel und Diagnostikum
WO2007109118A2 (en) * 2006-03-16 2007-09-27 Cc 10 Sweden Ab RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
WO2011047065A1 (en) * 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARIAS-MARTINEZ JOEL ET AL: "Clara Cell Protein Expression in Human Neonates During Respiratory Distress Syndrome", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, vol. 29, no. 5-6, 2012, pages 753 - 760, XP002762721 *
BROECKAERT F ET AL: "Clara cell secretory protein (CC16): Characteristics and perspectives as lung peripheral biomarker", CLINICAL & EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY, WILEY INTERSCIENCE, UK, vol. 30, no. 4, 1 April 2000 (2000-04-01), pages 469 - 475, XP002347708, ISSN: 0954-7894, DOI: 10.1046/J.1365-2222.2000.00760.X *
GIANNONE PETER J ET AL: "Oxidative modifications of recombinant human Clara Cell Secretory Protein (rhCC10) by myeloperoxidase (MPO) and HOCl in vitro.", PEDIATRIC RESEARCH, vol. 53, no. 4 Part 2, April 2003 (2003-04-01), & ANNUAL MEETING OF THE PEDIATRIC ACADEMIC SOCIETIES; SEATTLE, WA, USA; MAY 03-06, 2003, pages 416A, XP008181860, ISSN: 0031-3998 *
LINDAHL MATS ET AL: "Demonstration of different forms of the anti-inflammatory proteins lipocortin-1 and Clara cell protein-16 in human nasal and bronchoalveolar lavage fluids", ELECTROPHORESIS, VERLAG CHEMIE, vol. 20, no. 4-5, 1 April 1999 (1999-04-01), pages 881 - 890, XP002405357, ISSN: 0173-0835, DOI: 10.1002/(SICI)1522-2683(19990101)20:4/5<881::AID-ELPS881>3.0.CO;2-6 *
RAMSAY PATRICIA L ET AL: "Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 164, no. 1, 1 July 2001 (2001-07-01), pages 155 - 161, XP002762722, ISSN: 1073-449X *

Also Published As

Publication number Publication date
US9394349B2 (en) 2016-07-19
MX2015013092A (es) 2016-06-02
JP2020055833A (ja) 2020-04-09
EP2968449A4 (de) 2017-03-22
KR20160030076A (ko) 2016-03-16
US20200325190A1 (en) 2020-10-15
JP2016515532A (ja) 2016-05-30
IL241417A0 (en) 2015-11-30
RU2015144360A (ru) 2017-04-24
US20160362462A1 (en) 2016-12-15
BR112015021266A2 (pt) 2017-10-10
US20140275477A1 (en) 2014-09-18
SG11201507277YA (en) 2015-10-29
US10676513B2 (en) 2020-06-09
AU2014233127A1 (en) 2015-09-24
CN105744946A (zh) 2016-07-06
WO2014145368A2 (en) 2014-09-18
JP6670987B2 (ja) 2020-03-25
US20190337999A1 (en) 2019-11-07
WO2014145368A3 (en) 2014-11-27
US10294285B2 (en) 2019-05-21
EP2968449A2 (de) 2016-01-20
CA2907439A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US10676513B2 (en) Modification and compositions of human secretoglobin proteins
Barbosa et al. Structure and function of a novel antioxidant peptide from the skin of tropical frogs
JP2016535087A (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
US20200087374A1 (en) Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
KR20160114082A (ko) 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도
US11046739B2 (en) BH4 stabilized peptides and uses thereof
Hossain et al. Chemically synthesized dicarba H2 relaxin analogues retain strong RXFP1 receptor activity but show an unexpected loss of in vitro serum stability
EP3307769B1 (de) Proteaseresistente lipidierte glp-1-analoga
US20160318987A1 (en) Protease resistant peptides
KR102268955B1 (ko) 항분비 인자 17
KR20190017017A (ko) 프로테아제-내성 모노-지질화된 펩타이드
CA2761629A1 (en) Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and/or hyperalgesia
Perdikoulis et al. Expression and characterisation of the thrombospondin type I repeats of human properdin
US20210363203A1 (en) Modification and compositions of human secretoglobin proteins
EP3538157B1 (de) Methylglyoxaladsorbierende cyclische peptide und deren verwendung zur vorbeugung und behandlung von erkrankungen im zusammenhang mit erhöhten methylglyoxalspiegeln
Boumaiza et al. Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1
Miranda et al. Peptide antagonists of the calcitonin gene‐related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics
Tom et al. Reproductible production of a PEGylated dual-acting peptide for diabetes
JP2020522476A (ja) ペプチドｐａｃ１アンタゴニスト
Wu et al. Three‐chain insulin analogs demonstrate the importance of insulin secondary structure to bioactivity
KR20230025935A (ko) 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
JP2012051826A (ja) 環状ペプチド及びその修飾ペプチド並びにＫｅｌｃｈ様ＥＣＨ結合タンパク質１の結合阻害物質のスクリーニング方法
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2968449

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17P Request for examination filed

Effective date: 20190521

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17Q First examination report despatched

Effective date: 20190617

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS